Stock Events

Stock Events

Soleno Therapeutics 

$53.01
55
-$0.00-0% Monday 13:30

Statistics

Day High
53.01
Day Low
52.98
52W High
90.32
52W Low
29.43
Volume
4,968,834
Avg. Volume
3,623,442
Mkt Cap
2.85B
P/E Ratio
27.47
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-1.27
-0.54
0.19
0.92
Expected EPS
0.918889
Actual EPS
N/A

Financials

10.97%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
380.81MRevenue
41.78MNet Income

Analyst Ratings

59.75Average Price Target
The highest estimate is 80.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
17%
Hold
83%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, directly competing with Soleno's therapeutic areas.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, competing in the same therapeutic area as Soleno.
PTC Therapeutics
PTCT
Mkt Cap7.04B
PTC Therapeutics operates in the field of genetic disorders, including rare diseases, making it a direct competitor to Soleno Therapeutics.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its advanced therapies, competing in the same niche as Soleno.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, including treatments for rare diseases, overlapping with Soleno's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, targeting genetic and rare diseases, which puts it in competition with Soleno.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing technology, which has applications in treating rare diseases, potentially competing with Soleno's therapeutic approach.

About

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Show more...
CEO
Dr. Anish Bhatnagar M.D.
Employees
115
Country
United States
ISIN
US8342033094

Listings

STU
DE
6XC.STU
MU
DE
6XC1.MU
BOATS
BOATS
SLNO.BOATS

0 Comments

Share your thoughts

FAQ

What is Soleno Therapeutics stock price today?▼
The current price of SLNO is $53.01 USD — it has decreased by -0% in the past 24 hours. Watch Soleno Therapeutics stock price performance more closely on the chart.
What is Soleno Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Soleno Therapeutics stocks are traded under the ticker SLNO.
Is Soleno Therapeutics stock price growing?▼
SLNO stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Soleno Therapeutics has showed a -38.7% decrease.
What is Soleno Therapeutics market cap?▼
Today Soleno Therapeutics has the market capitalization of 2.85B
When is the next Soleno Therapeutics earnings date?▼
Soleno Therapeutics is going to release the next earnings report on August 12, 2026.
What were Soleno Therapeutics earnings last quarter?▼
SLNO earnings for the last quarter are 0.59 USD per share, whereas the estimation was 0.68 USD resulting in a -13.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Soleno Therapeutics revenue for the last year?▼
Soleno Therapeutics revenue for the last year amounts to 380.81M USD.
What is Soleno Therapeutics net income for the last year?▼
SLNO net income for the last year is 41.78M USD.
How many employees does Soleno Therapeutics have?▼
As of July 27, 2026, the company has 115 employees.
In which sector is Soleno Therapeutics located?▼
Soleno Therapeutics operates in the Health & Wellness sector.
When did Soleno Therapeutics complete a stock split?▼
The last stock split for Soleno Therapeutics was on August 26, 2022 with a ratio of 1:15.
Where is Soleno Therapeutics headquartered?▼
Soleno Therapeutics is headquartered in Redwood City, United States.